StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) company profile

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3034% above fair value
$36.48+0.02 (+0.05%)

Close on Nov 16, 2026Market cap $1.45BP/E 104.2Yield –

About Pacira BioSciences

Pharmaceutical Preparations, SIC 2834

Pacira BioSciences develops and commercializes non-opioid pain therapies for patients undergoing surgical procedures or managing chronic joint conditions. The company provides three primary commercial products: EXPAREL, a long-acting injectable local analgesic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and iovera, a handheld cryoanalgesia device that administers targeted cold temperatures to relieve nerve pain without drugs. Its therapies serve surgical patients, including adult and pediatric populations, as well as individuals suffering from osteoarthritis and chronic musculoskeletal pain.

The business operates corporate headquarters and principal executive offices in Brisbane, California. It maintains commercial authorization and clinical registrations across the United States, Canada, and the European Union. In addition to commercializing products for hospital outpatient departments and ambulatory surgery centers, the enterprise oversees registry studies across 15 participating clinical sites in the United States.

Summary of the business section of Pacira BioSciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Pacira BioSciences, Inc.
Founded
2006
Headquarters
Brisbane, CA
Address
2000 Sierra Point Parkway, Suite 900 94005
Phone
(650) 242-8052
Website
pacira.com
Employees
829, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Short Hills, NJ

Stock & identifiers

Ticker
PCRX
Exchange
Nasdaq
IPO date
Feb 3, 2011
Shares outstanding
40M, Aug 3, 2026
Public float
$757.50M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1396814
CUSIP
695127100
ISIN
US6951271005
FIGI
BBG0018FQNS6
Share class FIGI
BBG001S77N12
LEI
549300P56LERYBDHCF69
EIN
51-0619477

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Frank D. LeeChief Executive Officer, Director0
Jonathan SloninChief Medical Officer0
Shawn CrossChief Financial Officer0
Kristen WilliamsChief Administrative Officer0
Brendan TeehanChief Commercial Officer0
Lauren RikerSenior Vice President, Finance0
Daryl GauglerChief Operating Officer115,443
Marcelo BigalDirector0
Michael J. YangDirector0
Thomas G. WiggansDirector–
Laura BregeDirector0
Mark FroimsonDirector0
Christopher ChristieDirector0
Samit HirawatDirector0
Alethia YoungDirector0
Mark A. KronenfeldDirector31,065
Abraham CeesayDirector9,039

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024
David Stack
$727.38K-$2.65M$2.59M$42$94
FY2024
Frank Lee
$15.94M$10.19M$2.59M$42$94
FY2023$6.88M$4.21M$1.54M$74$91
FY2022$6.85M$887.12K$2.03M$85$90
FY2021$6.94M$5.46M$2.06M$133$140
FY2020$9.34M$13.55M$2.45M$132$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Frank Lee
Chief Executive Officer
$896.54K$688.50K$3.18M$9.61M$648.24K$919.10K$15.94M–
David Stack
Former Chief Executive Officer
$634.04K$2.19K–––$91.15K$727.38K-89%
Shawn Cross
Chief Financial Officer
$100.96K$48.56K$1.24M$1.35M–$3.72K$2.74M–
Lauren Riker
Former Interim Chief Financial Officer
$374.56K$271.72K$612.61K–$159.19K$20.83K$1.44M–
Charles A. Reinhart, III
Former Chief Financial Officer
$374.17K$172.26K$350.47K––$387.64K$1.28M-10%
Kristen Williams
Chief Administrative Officer and Secretary
$519.26K$246.81K$2.61M–$220.75K$15.61K$3.61M+125%
Daryl Gaugler
Executive Vice President, Commercial Operations
$511.81K$236.80K$2.61M–$217.52K$20.83K$3.59M+134%
Jonathan Slonin
Chief Medical Officer
$535.00K$247.44K$1.72M$131.04K$227.30K$20.83K$2.88M+81%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 3, 2011
Offer price
$7.00
Securities offered
6,000,000
Gross proceeds
$42.00M
Exchange
Nasdaq
First trading day
Feb 3, 2011
First-day close
$7.02+0.3%
Lock-up ends (est.)
Aug 2, 2011

“Per share Total Price to the public $ 7.00 $ 42,000,000 Underwriting discounts and commissions $ 0.49 $ 2,940,000 Proceeds to us (before expenses) $ 6.51 $ 39,060,000 Certain of our existing principal stockholders and their affiliated entities have indicated an interest in purchasing an aggregate of up to $7.5 mill”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 829 employees, of which 825 were full-time and four were part-time.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 30, 2026Tender offerThird-party tender offer for the company's shares
Nov 19, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 22, 2021Tender offerThird-party tender offer for the company's shares
Apr 9, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 9, 2019Name changeName changed from Pacira Pharmaceuticals, Inc. to Pacira BioSciences, Inc.
Feb 26, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 18, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 3, 2011IPOInitial public offering priced (424B4 prospectus)
Jan 28, 2011ListingRegistration of securities on an exchange (Form 8-A)
Nov 5, 2008Name changeName changed from PACIRA INC to Pacira Pharmaceuticals, Inc.
Apr 16, 2007Name changeName changed from Blue Acquisition Corp to PACIRA INC

See a number that looks wrong?